Long Island Iced Tea Looks Poised To Benefit From Shift Away From Carbonated Beverages
Long Island Iced Tea is a beverage company that provides premium non-alcoholic ready-to-drink iced tea bottle beverages. The company recently closed a public of
www.PennySt0ckl0l.org is one of the best “alerts” services I have found. Just sign up and watch from the sidelines, you will see!
Monster MicroCaps SPECIAL ALERT to ACUR shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market. https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html
Any idea when the latest trial for the FDA will begin? I am assuming it will be sometime this month with results back in the following 2-3 week. Any thoughts????
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.8 In other words, the correlation coefficient of the other stoc
I am buying here.
Any idea where one can find the earnings report that should be coming out today?
One day we will wake up and ACUR will be listed for 2.20 a share. Looking forward to that One day. :.)
Probably just seen a bounce back. Still waiting on news about their strategic alternative options. I'm hoping for a sale of the company, probably for the best.
Largest Gainers on the NASDAQ & NYSE ---> T0pMarketGalners.c0m
Well we are officially on the OTC Board. Not Ideal, but I think (I hope) they are trying to find a buyer. Still holding tight, and seems I'm not alone.
February 22, 2017 Kevin B. Atencio The Brokerages Anticipate Acura Pharmaceuticals, Inc. (ACUR) to Post ($0.27) Earnings Per Share Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Needless to say, not happy with where this stock is currently trading! On the other hand, if you make a public statement that you have hired an IB to search alternatives, I would assume they will be able to get far more than .77! They have enough critical patents that the value of the stock should be in the $4-5 range - maybe more depending on who the buyer is. Just as critical question, "Are the parts worth more than the whole?" I am hoping they don't get greedy and simply move this POS down the road - preferably for stock in a much better run company...........